Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.
Chemotherapy-Induced Thrombocytopenia
DRUG: Hetrombopag|DRUG: Hetrombopag plus Placebo|DRUG: Placebo
The proportion of treatment responders., Randomization up to 80 days
Duration from the commencement of treatment to a platelet count ≥100×109/L;, Randomization up to 30 days|Proportion of subjects who could complete chemotherapy without dose modification and rescue therapy and;, Randomization up to 160 days|Proportion of subjects without serious bleeding events;, Randomization up to 190 days|Number of adverse events (AEs)/serious adverse events (SAEs), Randomization up to 190 days
The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.